Canton Strategic Holdings, Inc.
$3.51
▲
0.62%
2026-04-21 06:08:01
www.cantonstrategic.com
NCM: CNTN
Explore Canton Strategic Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$194.33 M
Current Price
$3.51
52W High / Low
$9.08 / $1.05
Stock P/E
—
Book Value
$10.72
Dividend Yield
—
ROCE
-3.9%
ROE
-17.99%
Face Value
—
EPS
$-1.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
1.6
Debt / Equity
—
Current Ratio
5.29
Quick Ratio
5.29
Forward P/E
—
Price / Sales
—
Enterprise Value
$152.09 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 2. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 3. | Polaryx Therapeutics, Inc. | $5.7 | — | $289.74 M | — | -171.33% | -1.94% | $48.91 / $2.2 | $0.1 |
| 4. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
| 5. | Relmada Therapeutics, Inc. | $7.37 | — | $773.03 M | — | -67.49% | -25.62% | $7.94 / $0.27 | $1.18 |
| 6. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 7. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.61 M | -2.09 M | -1.85 M | -2.55 M | -3.85 M | — |
| Net Profit | -29.42 M | -2.1 M | -1.86 M | -2.54 M | -3.82 M | — |
| EPS in Rs | -0.52 | -0.04 | -0.03 | -0.04 | -0.07 | -2.45 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -20.11 M | -12.43 M | -9.46 M | -6.88 M |
| Net Profit | -35.92 M | -12.2 M | -9.32 M | -8.47 M |
| EPS in Rs | -0.63 | -0.22 | -0.16 | -0.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 519.15 M | 3.72 M | 10.95 M | 6.69 M |
| Total Liabilities | 121.22 M | 2.41 M | 1.82 M | 1.14 M |
| Equity | 397.93 M | 1.31 M | 9.13 M | 5.54 M |
| Current Assets | 17.39 M | 3.72 M | 10.95 M | 6.69 M |
| Current Liabilities | 3.29 M | 2.41 M | 1.82 M | 1.14 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -16.13 M | -10.9 M | -7.3 M | -6.56 M |
| Investing CF | -77.57 M | 0 M | 0 M | 0 M |
| Financing CF | 107.17 M | 3.53 M | 11.72 M | 13.06 M |
| Free CF | -93.7 M | -10.9 M | -7.3 M | -6.56 M |
| Capex | -77.57 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -30.89% | -9.98% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-05-28 | 1:0.0666667 |
| 2023-11-21 | 1:0.04 |